Source: Eur Respir J, 57 (5) 2002559; 10.1183/13993003.02559-2020



Rating:

Share or cite this content

Citations should be made in the following way:
Nikhil Hirani, Alison C. MacKinnon, Lisa Nicol, Paul Ford, Hans Schambye, Anders Pedersen, Ulf J. Nilsson, Hakon Leffler, Tariq Sethi, Susan Tantawi, Lise Gravelle, Robert J. Slack, Ross Mills, Utsa Karmakar, Duncan Humphries, Fredrik Zetterberg, Lucy Keeling, Lyn Paul, Philip L. Molyneaux, Feng Li, Wendy Funston, Ian A. Forrest, A. John Simpson, Michael A. Gibbons, Toby M. Maher. Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis. Eur Respir J, 57 (5) 2002559; 10.1183/13993003.02559-2020

Member's Comments

No comment yet.

Related content which might interest you: Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis Source: Eur Respir J, 50 (4) 1701157; 10.1183/13993003.01157-2017 Year: 2017 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function Source: Eur Respir J 2016; 48: 843-851 Year: 2016 Decreased BCL-2 expression in alveolar macrophages of patients with idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010 Inhalation therapy of interferon-gamma in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 266s Year: 2005 Increased polysialylation in lung tissue of patients with idiopathic pulmonary fibrosis Source: Annual Congress 2011 - Cell biology of lung disease Year: 2011 Serum surfactant protein D may predict the effect of pirfenidone in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Nintedanib (BIBF 1120) prevents TGF-beta-induced pro-fibrotic effects in primary human lung myofibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 1 Year: 2014 Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment II Year: 2016 Effect of nintedanib, pirfenidone, N-acetylcysteine and their combinations on cultured myofibroblast-type cells derived from patients with asbestosis and idiopathic pulmonary fibrosis Source: International Congress 2015 – Airway remodelling: recent developments Year: 2015 Cyclo-oxygenase (Cox)-2 is not upregulated in idiopathic pulmonary fibrosis Source: Eur Respir J 2001; 18: Suppl. 33, 410s Year: 2001 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Effect of nintedanib on hyaluronic acid metabolism in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Changes in biomarkers in patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib and sildenafil Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia Year: 2019 Expression of apoptotic markers in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 376s Year: 2003 Serum levels of surfactant proteins in patients with combined pulmonary fibrosis and emphysema (CPFE) Source: International Congress 2015 – IPF pathogenesis Year: 2015 Pirfenidone in idiopathic pulmonary fibrosis Source: Eur Respir J 2010; 35: 821-829 Year: 2010 Pirfenidone in idiopathic pulmonary fibrosis Source: Eur Respir J 2010; 36: 695-696 Year: 2010 Role of JAK2/STAT3 pathway in vascular function of pulmonary fibrosis patients Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015